Found: 83
Select item for more details and to access through your institution.
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
- Published in:
- 2018
- By:
- Publication type:
- journal article
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Clinical and demographic characteristics related to onset site and spread of cervical dystonia.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinimetric testing of the comprehensive cervical dystonia rating scale.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Orthostatic hypotension in Parkinsonism: What is it and how can we treat it?
- Published in:
- 2015
- By:
- Publication type:
- Editorial
Clinical spectrum of levodopa-induced complications.
- Published in:
- Movement Disorders, 2015, v. 30, n. 1, p. 80, doi. 10.1002/mds.26125
- By:
- Publication type:
- Article
Understanding conversion disorders: Back to Freud's theory.
- Published in:
- 2014
- By:
- Publication type:
- Editorial
New methods of preventing neurodegeneration? lessons from prion diseases.
- Published in:
- Movement Disorders, 2014, v. 29, n. 1, p. 35, doi. 10.1002/mds.25782
- By:
- Publication type:
- Article
Subthalamic nucleus and striatum: The red and green signals to regulate the traffic of basal ganglia circuitry.
- Published in:
- Movement Disorders, 2013, v. 28, n. 13, p. 1802, doi. 10.1002/mds.25694
- By:
- Publication type:
- Article
Metabolic disorders causing movement disorders in childhood; An addition to the list.
- Published in:
- Movement Disorders, 2013, v. 28, n. 5, p. 584, doi. 10.1002/mds.25434
- By:
- Publication type:
- Article
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials.
- Published in:
- Movement Disorders, 2013, v. 28, n. 2, p. 131, doi. 10.1002/mds.25273
- By:
- Publication type:
- Article
A critique of available scales and presentation of the non-human primate dyskinesia rating scale.
- Published in:
- Movement Disorders, 2012, v. 27, n. 11, p. 1373, doi. 10.1002/mds.25133
- By:
- Publication type:
- Article
Improved viability of stem cell transplants in animal models of Parkinson's disease.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Increased levels of 5-HT<sub>1A</sub> receptor binding in ventral visual pathways in Parkinson's disease.
- Published in:
- Movement Disorders, 2012, v. 27, n. 6, p. 735, doi. 10.1002/mds.24964
- By:
- Publication type:
- Article
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.
- Published in:
- Movement Disorders, 2011, v. 26, p. S2, doi. 10.1002/mds.23829
- By:
- Publication type:
- Article
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
- Published in:
- Movement Disorders, 2011, v. 26, p. S42, doi. 10.1002/mds.23884
- By:
- Publication type:
- Article
The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease.
- Published in:
- Movement Disorders, 2011, v. 26, n. 7, p. 1225, doi. 10.1002/mds.23631
- By:
- Publication type:
- Article
Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype.
- Published in:
- Movement Disorders, 2011, v. 26, n. 4, p. 753, doi. 10.1002/mds.23510
- By:
- Publication type:
- Article
The α<sub>2</sub> adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
- Published in:
- Movement Disorders, 2010, v. 25, n. 13, p. 2084, doi. 10.1002/mds.23172
- By:
- Publication type:
- Article
Increased 5-HT<sub>2A</sub> receptors in the temporal cortex of parkinsonian patients with visual hallucinations.
- Published in:
- Movement Disorders, 2010, v. 25, n. 10, p. 1399, doi. 10.1002/mds.23083
- By:
- Publication type:
- Article
Effect of histamine H<sub>2</sub> receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
- Published in:
- Movement Disorders, 2010, v. 25, n. 10, p. 1379, doi. 10.1002/mds.23069
- By:
- Publication type:
- Article
Serotonin and Parkinson's disease: On movement, mood, and madness.
- Published in:
- Movement Disorders, 2009, v. 24, n. 9, p. 1255, doi. 10.1002/mds.22473
- By:
- Publication type:
- Article
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2008, v. 23, n. 13, p. 1922, doi. 10.1002/mds.22086
- By:
- Publication type:
- Article
A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease.
- Published in:
- Movement Disorders, 2008, v. 23, n. 2, p. 297, doi. 10.1002/mds.21837
- By:
- Publication type:
- Article
Levodopa-related motor complications-Phenomenology.
- Published in:
- Movement Disorders, 2008, v. 23, n. S3, p. S509, doi. 10.1002/mds.22021
- By:
- Publication type:
- Article
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease.
- Published in:
- Movement Disorders, 2007, v. 22, n. 15, p. 2268, doi. 10.1002/mds.21730
- By:
- Publication type:
- Article
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2006, v. 21, n. 11, p. 1879, doi. 10.1002/mds.21073
- By:
- Publication type:
- Article
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure.
- Published in:
- Movement Disorders, 2006, v. 21, n. 10, p. 1578, doi. 10.1002/mds.20936
- By:
- Publication type:
- Article
Histamine H3 receptor agonists reduce.
- Published in:
- Movement Disorders, 2006, v. 21, n. 6, p. 839, doi. 10.1002/mds.20828
- By:
- Publication type:
- Article
Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea (A videotape accompanies this article.).
- Published in:
- Movement Disorders, 2003, v. 18, n. 12, p. 1550, doi. 10.1002/mds.10606
- By:
- Publication type:
- Article
Fipamezole (JP-1730) is a potent α<sub>2</sub> adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2003, v. 18, n. 8, p. 872, doi. 10.1002/mds.10464
- By:
- Publication type:
- Article
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 2002, v. 17, n. 6, p. 1180, doi. 10.1002/mds.10289
- By:
- Publication type:
- Article
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha<sub>2</sub> adrenoceptor antagonist idazoxan.
- Published in:
- Movement Disorders, 2001, v. 16, n. 4, p. 642, doi. 10.1002/mds.1148
- By:
- Publication type:
- Article
5-HT<sub>2C</sub> receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.
- Published in:
- Movement Disorders, 2000, v. 15, n. 6, p. 1064, doi. 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C
- By:
- Publication type:
- Article
The α<sub>2</sub>-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
- Published in:
- Movement Disorders, 1999, v. 14, n. 5, p. 744, doi. 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7
- By:
- Publication type:
- Article
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time.
- Published in:
- Journal of Neuroscience, 2011, v. 31, n. 19, p. 7190, doi. 10.1523/JNEUROSCI.1171-11.2011
- By:
- Publication type:
- Article
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
- Published in:
- FASEB Journal, 2012, v. 26, n. 5, p. 2154, doi. 10.1096/fj.11-195016
- By:
- Publication type:
- Article
Striatal histone modifications in models of levodopa-induced dyskinesia.
- Published in:
- Journal of Neurochemistry, 2008, v. 106, n. 1, p. 486, doi. 10.1111/j.1471-4159.2008.05417.x
- By:
- Publication type:
- Article
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1027, doi. 10.1007/s40265-022-01747-7
- By:
- Publication type:
- Article
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease.
- Published in:
- Movement Disorders Clinical Practice, 2023, v. 10, n. 9, p. 1408, doi. 10.1002/mdc3.13828
- By:
- Publication type:
- Article
Unmet Needs in Parkinson's Disease.
- Published in:
- Movement Disorders Clinical Practice, 2023, v. 10, n. 1, p. S47, doi. 10.1002/mdc3.13838
- By:
- Publication type:
- Article
Unmet Needs in Parkinson's Disease.
- Published in:
- 2023
- By:
- Publication type:
- Proceeding